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Abstract
Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy are neurodegenerative disorders resulting 
in progressive motor/cognitive deficits among other symptoms. They are characterised by stereotypical brain cell loss 
accompanied by the formation of proteinaceous aggregations of the protein α-synuclein (α-syn), being, therefore, termed 
α-synucleinopathies. Although the presence of α-syn inclusions is a common hallmark of these disorders, the exact nature 
of the deposited protein is specific to each disease. Different neuroanatomical regions and cellular populations manifest a 
differential vulnerability to the appearance of protein deposits, cell dysfunction, and cell death, leading to phenotypic diver-
sity. The present review describes the multiple factors that contribute to the selective vulnerability in α-synucleinopathies. 
We explore the intrinsic cellular properties in the affected regions, including the physiological and pathophysiological roles 
of endogenous α-syn, the metabolic and genetic build-up of the cells and their connectivity. These factors converge with the 
variability of the α-syn conformational strains and their spreading capacity to dictate the phenotypic diversity and regional 
vulnerability of each disease. Finally, we describe the exogenous and environmental factors that potentially contribute by 
igniting and modulating the differential pathology in α-synucleinopathies. In conclusion, we think that it is the confluence 
of this disruption of the cellular metabolic state and α-syn structural equilibrium through the anatomical connectivity which 
appears to initiate cascades of pathological processes triggered by genetic, environmental, or stochastic events that result in 
the “death by a thousand cuts” profile of α-synucleinopathies.
Parkinson’s disease (PD), dementia with Lewy bodies 
(DLB), and multiple system atrophy (MSA) belong to the 
group of devastating neurodegenerative disorders known 
as α-synucleinopathies. They share multiple characteristics 
such as a preference for affecting the motor and/or cognitive 
spheres and an orderly recruitment of brain regions to the 
disease in a stereotyped manner, pathologically featuring 
brain cell loss accompanied by proteinaceous aggregates of 
the protein α-synuclein (α-syn). Different neuroanatomical 
regions, and within these regions different neuronal and glial 
populations, show a differential vulnerability to dysfunction 
and cell death in α-synucleinopathies, resulting in pheno-
typic diversity. The way in which disease starts and pro-
gresses and the relative dysfunction of neuronal circuitries 
is probably the resulting combination and interplay of mul-
tiple factors including (1) intrinsic cellular properties in the 
affected regions, such as the normal and aberrant properties 
of the endogenous α-syn protein, the metabolic and genetic 
build-up of the cells, and their connectivity, (2) the existence 
of different α-syn conformational strains and a differential 
facilitation, permissiveness or blocking of each cell type in 
generating and/or transferring them to other cells, thereby 
generating specific neuroanatomical routes for their spread, 
and (3) putative exogenous and environmental factors acting 
as triggers or modulators of pathology.
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Intrinsic cellular properties underlying 
selective vulnerability
The differential vulnerability of cellular populations and 
regions to degeneration in α-synucleinopathies is in no doubt 
influenced by intrinsic cellular properties in the affected 
regions, such as the normal and aberrant properties of the 
endogenous α-syn protein, their metabolic and genetic build-
up and their connectivity.
Function and dysfunction of endogenous α‑syn
Here, we discuss the molecular nature of α-syn which 
give rise to its physiological and pathophysiological prop-
erties and the cellular characteristics of nuclei affected 
in α-synucleinopathies which may predispose them to 
degeneration.
The structural basis of α‑syn
The physiological and pathological nature of α-syn is deter-
mined by its molecular and structural properties. The com-
plexity of α-syn pathology mirrors its ability to form a broad 
range of structures, its diverse post-translational modifica-
tion status, and its ability to associate with both lipid and 
protein partners. Understanding how α-syn affects specific 
biological pathways and downstream physiological functions 
provides insights into the differential cellular and regional 
vulnerabilities in α-synucleinopathies [108, 150, 158].
α-Syn is a small protein (140 amino acids) expressed 
throughout the brain and at lower levels in other tissues 
including gut, heart and blood cells. α-Syn consists of 3 
domains: (1) the amphipathic N-terminal domain contains 
7 conserved but imperfect repeats of 11 amino acids, each 
containing the consensus sequence KTKEGV [59]. The 
N-terminus domain is thought to be important for α-syn-
lipid interactions, whereby the repeats promote α-helix over 
β-sheet structure of the protein, particularly when exposed 
to negatively charged lipids [11]. (2) Residues 61–95 form 
the core region, known as non-amyloid-β component (NAC). 
NAC is important for fibril formation and aggregation of 
α-syn due to its propensity to form cross-beta sheets. (3) The 
C-terminus tail is highly acidic, and proline rich resulting 
in a disordered, random coil structure. Interactions between 
C-terminus, and NAC domains prevent α-syn aggregation, 
consistent with the high structural homology of C-terminus 
with heat-shock proteins capable of limiting α-syn aggrega-
tion [30].
While mostly thought to adopt an unfolded monomeric 
structure, α-syn can exist in multiple molecular weight spe-
cies including monomeric, oligomeric, and fibrillar struc-
tures. These species are believed to assemble in a stochastic 
manner and to potentially inter-convert and exist in an equi-
librium in which the concentration and lifespan of each con-
formation would depend on multiple physical and chemical 
factors in the cellular milieu [134]. Factors which shift the 
structural equilibria ultimately result in the assembly of dif-
ferent physiological and pathological strains.
The physiological role of α‑syn
α-Syn in the brain is predominantly pre-synaptically located, 
where it has a propensity to bind to curved membranes 
including vesicles and is often associated with known com-
ponents of the exocytotic machinery [33, 59]. α-Syn accu-
mulation in pre-synaptic terminals causes a synaptopathy 
thought to ultimately lead to a dying back-like mechanism 
of neurodegeneration [27]. Additional pathogenic mecha-
nisms of α-syn seem to derive from its intimal physiological 
association with mitochondria, endoplasmic reticulum (ER), 
and lysosomal structures [32, 174], where it interacts with a 
range of protein and lipid partners.
The effect of α-syn on the release of several neurotrans-
mitters including dopamine (DA), noradrenaline, serotonin, 
and glutamate has been explored [87, 98, 167]. However, 
even for a given neurotransmitter, α-syn has been reported 
to have wide-ranging effects. For example, α-syn has been 
reported to both decrease, increase and have no effect on 
DA release depending upon the species of α-syn and the 
region of recording [87, 98]. These varying effects illustrate 
the complex interaction between α-syn and individual neu-
rotransmitter systems. The mechanisms underlying α-syn 
effects on neurotransmission have undergone much investi-
gation in part driven for the insights into possible pharma-
cological interventions. α-Syn has been shown to increase 
the voltage-gated calcium channel (VGCC) function, e.g., by 
decreasing raft partitioning of Cav2.2 channels [152], which 
could contribute to the facilitatory effects of α-syn on neuro-
transmitter release. In contrast, α-syn assemblies have been 
found to bind  N+/K+ATPase (NKA), leading to areas of low 
NKA density, affecting membrane repolarisation, which may 
decrease release [158]. The Soluble N-ethylmaleimide-sen-
sitive Factor (NSF) Attachment Protein Receptor (SNARE) 
machinery is a large protein complex which play a key role 
in membrane fusions, such as the docking of synaptic vesi-
cles with the pre-synaptic membrane in neurons. α-Syn is 
known to bind to curved membranes and is strongly associ-
ated with vesicles, where it is thought to associate precisely 
with the SNARE machinery for the effective tethering of 
vesicles [33] with further effects on neurotransmission. The 
association of α-syn and vesicles, interestingly, appears to 
result in the release of α-syn into the extracellular space, 
in a process highly dependent on intrinsic neuronal activi-
ties. While the physiological role of this phenomenon is not 
fully understood, the released α-syn is subsequently taken 
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up by surrounding neurons and glia [99, 136, 188], which is 
thought to have pathological implications. For example, it is 
possible that these putative physiological routes are hijacked 
by pathological species for their own spread.
In addition to interacting with pre-synaptic mechanisms 
controlling neurotransmitter release, α-syn has also been 
reported to change cell firing properties. In dopaminergic 
(DAergic) neurons, mutant and wild-type α-syn have been 
reported to increase and decrease cell firing, respectively 
[87, 163]. The increase in DAergic neuron firing by mutant 
α-syn is due to inhibition of A-type  K+ channels, whereas 
the mechanisms of age-related decrease in DAergic neuron 
firing by wild-type α-syn have not yet been established. 
However, interactions with NKA, VGCCs, or membrane 
dynamics could all contribute. It should also be noted that 
alterations in neuronal firing could also be due to network 
adaptations, following changes to neurotransmitter release. 
This chain of events illustrates the ability for α-syn to insti-
gate a cascade of events and the complexity of establish-
ing hierarchy of α-syn pathology when neuronal and α-syn 
biology is so intricately connected. Nevertheless, it seems 
plausible that the complex and variable effects of α-syn on 
neurotransmission may account in part for the phenotypic 
diversity resulting from the differentially impacted circuit-
ries upon α-syn dysfunction.
Besides the direct implication of α-syn in the synaptic 
machinery, α-syn is involved in mitochondrial function. 
Given that generation of energy in the form of ATP is essen-
tial for all the stages of neurotransmission, these interactions 
between α-syn and mitochondria further impact neurophysi-
ology. α-Syn (monomer) increases ATP synthase efficiency 
[107] and α-syn also affects mitochondrial trafficking and 
morphology [174]. Rare genetic forms of early onset PD are 
due to mutations in mitochondrial genes and genes relevant 
for mitochondrial metabolism (e.g., PRKN and PINK1, both 
involved in mitophagy), illustrating an interesting cross-over 
between mitochondrial function and α-synucleinopathies. 
Thus, α-syn has wide-ranging effects on mitochondrial func-
tion and dysfunction, which has profound implications for 
neuronal physiology.
A putative physiological role for α‑syn oligomers/
multimeric species
Most of the studies investigating the physiological role of 
α-syn have focused their attention on the monomeric form. 
However, recent studies suggest putative physiological 
roles for oligomers/multimeric species, with a dynamic 
equilibrium existing between free monomeric species and 
membrane-bound multimers influenced by the cellular envi-
ronment. For example, α-syn multimers engage with syn-
aptic vesicles clustering them, thus halting their recycling 
under physiological conditions [182]. It also seems that the 
referred physiological function of α-syn in binding to and 
promoting SNARE complex formation may not be medi-
ated by monomeric α-syn but rather by higher order mul-
timers of α-syn assembling upon membrane binding [33]. 
The specific nature of these oligomeric/multimeric species 
engaged in physiological roles, whether they can be precur-
sors within the abnormal aggregation pathway (or rather be 
off-pathway), and the conditions for any pathological con-
version are not fully understood. Recent work has suggested 
a folded helical tetramer as the physiological α-syn species 
[52], but other groups have questioned the existence of this 
tetrameric form [34].
Bona fide prion diseases are characterised by infectious 
agents composed solely of protein that are transmissible 
between individuals. The molecular basis of prions is their 
ability to acquire a self-templating amyloidogenic state. 
Several human diseases of the brain and other organs are 
now being shown to be characterised by abnormal protein 
aggregation that can spread between neighbouring cells 
and in certain conditions propagate pathology when protein 
extracts are experimentally inoculated into another individ-
ual. Several of the proteins involved in neurodegenerative 
disorders (e.g., tau, α-syn and β-amyloid) have been shown 
to have self-templating properties. At least for now, these 
proteins have not been shown to have all the properties of 
prions (such as their microbiological transmissibility), and 
therefore, different names have been proposed to describe 
them, including prionoids or prion-like proteins.
There are, however, other proteins characterised by 
self-templating with physiological rather than deleterious 
consequences. The biochemical process involved seems 
particularly well suited to produce a long-lasting physiologi-
cal change upon a transient stimulus [103]. Several are the 
examples in fungi [45, 57] and in the marine snail Aplysia, 
where the protein cytoplasmic polyadenylation element-
binding protein (CPEB) functions to maintain long-term 
changes in synaptic efficacy through a mechanism involving 
self-perpetuating aggregation [159]. This mechanism effec-
tively works as a conformational switch for synapse-spe-
cific local protein synthesis [160]. Additional examples for 
physiological functions of self-templating proteins include 
epigenetic regulation and scaffolding for subcellular organ-
ization [110]. Importantly, there are at least two features 
that theoretically would differentiate these non-pathogenic 
prion-like processes from the pathogenic ones: (1) that the 
switch to the self-templating conformation of the protein 
is initiated by a physiological signal [160] and (2) that the 
process should be subject to regulatory control of its spatial 
and temporal propagation [15].
Therefore, we hypothesise that it would not be unthink-
able to imagine a physiological role not only for “innocent” 
α-syn oligomer/multimers, but also for α-syn prionoids 
(defined as amyloidogenic, self-templating aggregates), 
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perhaps in a process involving a regulated inter-conversion 
between the different aggregated or monomeric states upon 
physiological signals, with their dysregulation precipitat-
ing disease. These processes could have roles in generating 
long-term changes at the synapse, as shown with other self-
templating proteins. In addition, seeding and propagation of 
a particularly folded conformation to other parts of the cell 
and to neighbouring cells could potentially be a resourceful 
mechanism being exploited physiologically by cells for yet 
undiscovered but possible functions, from paracrine signal-
ling to a mode of innate defensive mechanism upon cellular 
stresses such as those derived from infection, traumatic brain 
injury, inflammation, or ischemia.
The toxic properties of α‑syn
Several sources of evidence support that at least part of 
the toxicity associated with α-synucleinopathies is due to 
α-syn gaining aberrant properties. However, growing evi-
dence suggests that loss of the required physiological func-
tion of α-syn could contribute to neuronal dysfunction and 
possibly toxicity (Fig. 1). The interplay and proportional 
contribution of gain and loss of function mechanisms in 
α-synucleinopathies [14] and what role, if any, they play in 
generating a differential cellular and regional susceptibility 
are still not fully characterised.
One of the key discoveries of our understanding of the 
molecular and pathological mechanisms of PD was the dis-
covery that the A53T mutation, and later, the A30P, E46K, 
G51D, A53E, and H50Q missense mutations in the α-syn 
gene (SNCA) caused autosomal dominant forms of the dis-
ease [126]. It must be said that the pathogenicity of the 
H50Q has been challenged [18], as it was also found as a 
rare variant in apparently healthy individuals. Subsequently, 
SNCA copy number variations (CNVs) including duplica-
tions and triplications were identified [126]. The autosomal 
dominant mode of inheritance and the high pathogenic pen-
etrance of most of these mutations seemed to point towards 
a gain of function mechanism in these familial cases, while 
the high clinical and pathologic similarities with sporadic 
disease suggested that such mechanisms could also play a 
prominent role in the common disease.
What are the ultimate mechanisms mediating this gain 
of function in SNCA-mutated cases? and could they explain 
part of the differential cellular and regional vulnerability? 
In the case of CNVs (duplications and triplications), there 
α-Syn gain of funcon mechanisms α-Syn loss of funcon mechanisms 
Mutaon 
Aggregaon 
Monomer Oligomer 
ATP synthase ATP synthase 
Lewy Body 
Mitochondria 
NKA funcon 
Lysosomal and 
ER stress 
Mutaon 
Monomer 
Oligomer/mulmer 
Tetramer? 
Physiological prionoids? 
Monomer 
Normal 
physiological 
funcon 
Impaired 
physiological 
funcon 
? 
Oligomer/mulmer 
Tetramer? 
Physiological prionoids? 
Sporadic 
disease 
Dysregulaon of  
physiological prionoids? 
Fig. 1  α-Syn potential gain/loss of function mechanisms. While 
α-syn is able to increase ATP synthase activity in its monomeric 
state, it reduces its activity in its oligomeric state. Oligomers have 
also been reported to reduce NKA function and cause lysosomal and 
ER stress. Mutations in α-syn have also been shown to alter the ratio 
of monomers with supramolecular species and to impair synaptic 
function. Similar mechanisms could play a role in sporadic disease. 
We hypothesise the existence of regulated physiological α-syn prio-
noids and their dysregulation contributing to disease perhaps by both 
gain and loss of function mechanisms
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is a clear dosage effect on the phenotype, with a total of four 
copies (heterozygous triplication cases, or rare homozygous 
duplication cases) having a more severe earlier disease than 
the three copies present in a heterozygous duplication car-
rier [93]. In the case of the reported missense mutations in 
SNCA, a variety of consequences have been derived from 
their altered structure. A recurrent finding is that mutations 
alter the way in which α-syn interacts with itself, changing 
the relative proportion of the possible species (e.g., mono-
mer, tetramer, oligomer and fibril), with most of these mis-
sense mutations promoting fibrillar [63] and/or oligomeric 
forms of the protein. In the case of sporadic disease, it is 
not established what is the initiating (e.g., stochastic?) and 
perpetuating mechanism(s) by which the interaction of wild-
type α-syn with itself is altered, but similar to familial cases, 
the resulting unbalance between the different species seems 
to be core to the disease pathogenesis.
Importantly, regardless of being composed of mutated or 
wild-type protein, these fibrillar and oligomeric forms affect 
cellular function (usually causing dysfunction). For example, 
these species affect the interaction of α-syn with lipid (loss 
of membrane binding) and protein-binding partners [107]. 
As mentioned, only α-syn assemblies (oligomer, fibrils) 
associate NKA, disrupting its positioning in the membrane 
with deleterious effects [158], and whereas monomeric 
α-syn increases ATP synthase efficiency, oligomeric α-syn 
inhibits ATP synthase. The latter effect results from oxi-
dation of the β-subunits resulting in lipid peroxidation and 
increasing the probability of permeability transition pore 
(PTP) opening, triggering mitochondrial swelling and ulti-
mately cell death [107], and illustrates the gain of function 
toxicity for these supramolecular species in the mitochon-
dria. Aggregates of α-syn accumulate within Lewy bodies 
(LBs). One report has claimed that LBs could be toxic by 
impairing cellular function through divergent mechanisms: 
In PD, by an interaction of α-syn with DNA to cause nuclear 
degradation (not clear though how cytoplasmic LBs could 
interact with the nuclear material), while in DLB, by draw-
ing mitochondria into the LB compromising their integrity 
[141]. However, LBs could also be interpreted as markers of 
surviving neurons, given that they are present in the remain-
ing neurons at post-mortem in patients with PD, or often 
in post-mortem tissue from asymptomatic individuals, and 
given that there is mixed evidence correlating severity of 
disease and propensity of proteinaceous inclusions [131]. In 
any case, what is clear is that the accumulation of aggregates 
into LBs [and glial cytoplasmic inclusions (GCIs)], even if 
not pathogenic themselves, probably reflects an inability of 
cells to effectively clear waste proteins due to dysfunction 
in clearing mechanisms (e.g., autophagy) with subsequent 
induction of ER and lysosomal stress [187]. The substantia 
nigra pars compacta (SNc) in PD brains could be a particu-
larly vulnerable region, as there is a suggestion it shows a 
decrease of chaperone-mediated autophagy (CMA) activ-
ity [7], which could fail to remove pathogenic α-syn which 
itself could further inhibit CMA [46]. A potential compensa-
tory upregulation of macroautophagy could be potentially 
also inhibited by pathogenic forms of α-syn, LRRK2 and 
glucocerebrosidase (GBA), as it has been shown for famil-
ial variants [6, 154, 184]. It would, therefore, be logical to 
deduce that those cell types and anatomical areas with more 
propensity to form these pernicious high molecular species 
(either by an increased production of the monomeric sub-
strate, or by deficient controlling and clearance mechanisms) 
would be more prone to degeneration.
As already mentioned, α-syn is a widely expressed pre-
synaptic protein that has been shown to be important in sev-
eral aspects of neurotransmission. Therefore, it is possible 
that some aspects of α-synucleinopathies result from a loss 
of the normal function of α-syn, for example, if there was a 
dysregulation in the production of α-syn aggregates trapping 
the protein away from the conformation species needed for 
a particular physiological role. It has been shown that dis-
ease-causing mutations in α-syn result in an increase in the 
ratio of monomer:tetramer structures of α-syn, where helical 
tetramers of α-syn are proposed by some researchers to be 
the physiological form of α-syn. While the existence of α-syn 
tetramers has been questioned, these data would suggest that 
stabilising the physiological tetramers would be protective 
against α-synucleinopathies [52]. In cases harbouring SNCA 
pathogenic missense mutations, several mechanisms could 
potentially lead to a loss of function mechanism, including 
haploinsufficiency and epigenetic silencing [179]. A putative 
loss of an anti-aggregation function for wild-type α-syn was 
suggested in a PD patient with onset at 32 which carried the 
H50Q mutation in a homozygous state. The H50Q promotes 
aggregation ex vivo, and this is reduced when the wild type 
is also present. This may represent a low penetrance allele 
in the heterozygous state due to a putative protective role for 
the normal SNCA allele partially and variably counteracting 
mutations with low pathogenic potential, which could be 
lost in homozygous state. However, it should be noted that 
α-syn knockout (KO) animals do not report parkinsonian 
phenotypes and no known disease-causing α-syn mutations 
arise from mutations with a clear loss of function (e.g., lead-
ing to lack of protein expression), indicating that complete 
loss of function of α-syn is not associated with parkinsonian 
disorders. This may be due to redundancy between α, β, and 
γ-synuclein, as KO of all three synucleins is necessary to 
expose any age-dependent neuronal dysfunction [72].
Following the development of the Braak staging hypoth-
esis for PD (Braak’s PD staging), toxic spreading of α-syn 
has been an interesting avenue of study, albeit a controver-
sial one [24, 165]. As mentioned, it has been determined 
that α-syn can be released from both neurons and glia, and 
subsequently taken up by surrounding cells (both neurons 
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and glia) [37]. α-Syn release is now known to be increased 
following high neuronal activity and, in this context, differ-
ent α-syn species could spread at different rates in different 
neuronal and non-neuronal populations [108, 134, 136, 188]. 
Depending on intracellular or extracellular location, α-syn 
will differentially associate with binding partners by virtue 
of their expression patterns. Furthermore, α-syn may occupy 
different structures due to environmental factors, including 
pH, which differ intra- and extracellularly and affect α-syn 
state [59]. Extracellular α-syn taken up by microglia has 
been shown to initiate immune responses, which can result 
in neuroinflammation and may contribute to cell loss; this 
is especially thought to occur in MSA [175]. All these fac-
tors could contribute to the differential cellular and regional 
vulnerability in α-synucleinopathies.
Innate cellular properties for vulnerability 
of the substantia nigra
Some of the factors which determine vulnerability to 
degeneration in α-synucleinopathies are best characterised 
in the SNc DAergic neurons. These neurons are central to 
these disorders as their degeneration manifests as the aki-
netic−rigid syndrome of PD/DLB and also of MSA. Most 
of the studies have focused, however, on PD. Comparing 
properties of vulnerable SNc DAergic neurons with their 
PD-resistant neighbours in the ventral tegmental area (VTA) 
have illustrated that metabolic,  Ca2+ and anatomical factors 
are being important (Fig. 2). Here, we discuss some of the 
properties of SNc DAergic neurons that predispose them to 
degeneration and highlight factors which are thought to also 
apply to MSA and DLB.
Metabolic burden and  Ca2+
There is an enormous metabolic burden placed on midbrain 
DAergic neurons, due to a number of intersecting factors, 
including their impressive architecture,  Ca2+ handling 
capacity and DA itself being potentially toxic [138, 164]. 
Midbrain DAergic neurons have a tonic pacemaker activ-
ity, which following salient information switches to tran-
sient high-frequency bursting [157]. These signals need 
to be propagated to the striatum, where DAergic neuronal 
axons form enormous complex arbors of which only a frac-
tion of potential release sites form typical synapses and 
DA release is under profound pre-synaptic control by other 
neurotransmitters [106]. Maintaining this complex archi-
tecture is thought to place a significant energetic burden 
on the neurons. The cholinergic projection neurons from 
basal forebrain, which frequently degenerate in DLB are 
SNc neurons VTA neurons 
Oligodendrocytes 
High energec burden 
Complex arborisaon 
High endogenous α-syn 
Ca Ca channels      High Ca flux 
Low Ca buffering Ca 
ROS DA associated damage 
Neuromelanin 
High energec burden 
Complex arborisaon 
High endogenous α-syn 
Ca Na channels      Low Ca flux 
High Ca buffering Ca 
ROS DA associated damage 
Neuromelanin 
High energec burden 
High endogenous α-syn 
Fig. 2  α-Syn selective vulnerability of SNc neurons/VTA neurons/
oligodendrocytes. While complex arborisation, neuromelanin con-
tent, DA associated damage, high energetic burden and α-syn levels 
are common features of both SNc and VTA neurons, there are funda-
mental differences in calcium flux and buffering that may account for 
differential vulnerability in these cells. However, the fact remains that 
these properties have not been shown to be core feature of cells that 
degenerate in other α-synucleinopathies such as oligodendrocytes. 
More studies focusing on glial populations, and perhaps their calcium 
metabolism, are needed to determine whether this is a critical feature 
of α-synucleinopathies
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also tonically active neurons with extensive, highly branched 
axonal arbors, suggesting that these factors may be shared 
across a proportion of the cell populations affected by 
α-synucleinopathies [170]. Interestingly, many of the mecha-
nisms for metabolic strain are shared between SNc and VTA 
midbrain DAergic neurons, posing the question of why are 
SNc DAergic neurons particularly vulnerable when VTA 
neurons are relatively spared in PD? One aspect that differs 
between SNc and VTA DAergic neurons it their relation-
ship with  Ca2+. SNc DAergic neurons utilise the L-type cal-
cium channel (LTCC) to support their pacemaker function, 
whereas VTA neurons rely on  Nav channels [77]. Striatal DA 
release in dorsal striatum innervated by SNc DA neurons is 
regulated by an unusually broad range of VGCC subtypes 
which have relatively loose spatiotemporal relationship to 
DA release compared to the nucleus accumbens innervated 
predominantly by VTA DAergic neurons [29]. In addition, 
VTA neurons express higher levels of the  Ca2+-binding pro-
tein calbindin which may support intracellular  Ca2+ buff-
ering, and also regulate coupling between  Ca2+ entry and 
downstream signalling cascades, which further divert VTA 
DAergic neurons from energetically demanding processes 
[68]. In contrast, calbindin levels are low in SNc and other 
nuclei affected in PD such as the locus coeruleus and the 
dorsal motor nucleus of the vagus, or the levels drop with 
age, such as in the basal forebrain [69]. Interestingly, oligo-
dendrocytes, which are especially sensitive to degeneration 
in MSA, are also known to have an unusually high metabolic 
demand, suggesting that toxic nature of α-syn is exacerbated 
by high metabolic demand [26].
Cells with net elevated levels of intracellular  Ca2+ could 
be prone to a vicious cycle in which high  Ca2+ could induce 
α-syn to oligomerise into certain species capable of forming 
 Ca2+ permeable pores [49], with further increase of  Ca2+ 
influx and further oligomerisation ultimately leading to cell 
death.
Loss of striatal DA is central to much of the motor dys-
function in PD. However, DA itself is a potentially toxic 
molecule to DAergic neurons. DA is readily oxidised to form 
ROS compounds (DA-quinones) which have been shown to 
accelerate mitochondrial dysfunction leading to cell death 
[82]. The potential for intracellular DA to produce harmful 
species is dependent on several factors, particularly dopa-
mine active transporter (DAT) activity. When DAT:VMAT 
(vesicular monoamine transporter) ratio is high, there is 
more unpackaged DA within the cytosol. α-Syn has been 
shown to increase DAT function, leading to DA uptake being 
faster [38]. One could postulate an additional vicious cycle 
occurring, whereby α-syn potentiates DAT function, clear-
ing already compromised DA release faster, meaning that 
more DA release events are required for analogous down-
stream signalling, leading to compensatory upregulation 
of tyrosine hydroxylase (TH) leading to high intracellular 
DA levels resulting in more DA-ROS being created. Fur-
thermore, α-syn increasing DAT function could increase 
the propensity for these neurons to take up environmental 
toxins including paraquat and rotenone, further indicating 
the potential toxic synergy between α-syn and DA biology 
[65]. Similar mechanisms could apply to other brain nuclei 
(other than the SNc and VTA) in PD and MSA-affected 
brains which use monoamines as a neurotransmitter (e.g., the 
locus coeruleus or the A2 neuronal populations of the dor-
sal motor nucleus of the vagus). However, many vulnerable 
neuronal types are not monoaminergic. To this respect, it is 
worth noting that α-syn also has potential to dysfunctionally 
interact with other neurotransmitters including glutamate, 
whereby α-syn can increase glutamate release and α-syn 
release increases with neuronal activity generating a fur-
ther vicious cycle leading to glutamate-induced cytotoxicity 
of both surrounding neurons and glia [76]. It is unresolved 
if other neurotransmitters could also generate deleterious 
vicious cycles between α-syn and release; however, it is 
noteworthy that it is cerebellar glutamatergic inputs that are 
particularly vulnerable in MSA [101].
Anatomical factors and connectivity
A key factor thought to underlie specific neuronal loss in 
α-synucleinopathies is due to their connectivity, potentiating 
the spread of α-syn misfolded aggregates. Although the evi-
dence supporting that α-syn shares some properties with pri-
ons is increasing, there is still a controversy about the prion 
hypothesis in α-synucleinopathies. This is discussed below, 
together with the possibility that some of these apparent dis-
crepancies emerge from the methods used to visualise α-syn 
pathology. Nevertheless, it is possible that the spread of 
α-syn pathology is modulated by additional convergent fac-
tors. The local environment seems to be important. In addi-
tion to categorizing the striatum along anatomical axes, the 
striatum can be subdivided into two histochemically defined 
organizations known as striosomes (or patches) and the 
surrounding matrix, which are classically defined by their 
preferential expression of Mu-opioid receptors or calbindin-
D28K, respectively. Striosomal (patch) regions within the 
striatum are particularly vulnerable in PD, and although they 
seem to receive more innervation from the ventral SNc (more 
vulnerable to degeneration in PD), individual DAergic neu-
rons do not seem to selectively innervate either striosomes or 
matrix regions [28]. This suggests that even within a single 
neuron, axonal compartments are variably vulnerable, and 
therefore, the microenvironment is likely to be influential 
modifying the cellular vulnerability due to its connectivity. 
Interestingly, the same species of α-syn can form different 
pathological structures within certain cell types, illustrating 
the difficulty in tracking α-syn spreading pathology [136]. 
The extracellular microenvironment is likely to be heavily 
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influential on glia biology which, as already mentioned, is 
strongly implicated in α-synucleinopathies. For example, 
local anatomical factors seem to explain the pattern in which 
astroglial cells accumulate α-syn in LB diseases paralleling 
the stages of intraneuronal pathology [25], although it is 
not clear if this potential transfer of α-syn species between 
neurons and astroglia is a required step in the spread of dis-
ease. Therefore, the anatomical build-up, the local microen-
vironment and connectivity could act by imposing permis-
siveness bridges or barriers in the generation and spread 
of self-templating species. It would not be unthinkable that 
the efficiency at which a cell-type transfers the pathological 
species may be uncoupled to their sensitivity (or resistance) 
to dysfunction and cell death. In this way, some highly effi-
cient cell types in transferring these species (and particu-
larly if anatomically strategically situated), but resistant to 
their noxious effects, may become gateways/motorways for 
disease dissemination. These factors need also to be taken 
into account when attempting to reconstruct the sequence of 
event by interpreting post-mortem tissue.
Genetic predisposition to differential vulnerability
Pathogenic mutations and epigenetic modifications
In most cases with SNCA genetic alterations (such as the 
A53T, E46K, and H50Q missense mutations and the CNVs), 
a disease characterised by LBs was seen when neuropa-
thology was available [139]. The pattern of distribution of 
LBs followed broadly that of sporadic PD cases, and this 
pathology also had a clinical correlate paralleling sporadic 
disease. In this respect, it is worth mentioning that cases 
harbouring the A53T mutation have prodromal symptoms 
including olfactory dysfunction, depression, gastrointestinal 
dysfunction, and rapid eye movement (REM) sleep behav-
iour disorder (RBD) at the same frequency or even more 
than in sporadic disease [94], likely reflecting a very similar 
LB pathology distribution. While cases with missense muta-
tions could have variable LB extension and some mutations 
appear to be more aggressive than others, a clearer dose 
effect is found in CNVs cases, whereas although in gen-
eral terms showed typical LB pathology, duplication cases 
showed more frequently brainstem restricted disease that 
correlated with an akinetic–rigid syndrome and triplication 
cases showed a diffuse disease that correlated with dementia. 
Some variability of distribution of pathology and symptoms, 
even within the same family, is present in both missense 
and CNVs’ mutations, indicating additional factors. More 
recently, two mutations in SNCA, the G51D [91] and the 
A53E [132] have been associated with severe and early phe-
notypes including both PD and MSA features, with both 
neuronal and glial (including oligodendroglial) α-syn inclu-
sions and affecting neuroanatomical areas typically affected 
in both PD and MSA. Interestingly, CNV cases can also have 
MSA-like pathological features [22].
At least three conclusions can be drawn from the analysis 
of familial cases with SNCA mutations. The first is that if 
we accept that at least part of the pathological lesions results 
from the expression of the mutations within the affected 
cells, this provides powerful evidence supporting the idea 
of a partially cell-autonomous process, i.e., that differen-
tial cellular (and regional) vulnerability could emerge from 
expression of genetic determinants within each cell. It is, 
nevertheless, possible that genetically determined diseases 
are also susceptible to prion-like spread. If this is the case, 
the resulting pathology would be a combination of cell-
autonomous and non-cell-autonomous processes.
The second is that if different mutations in the same 
gene can give rise to PD or MSA-like phenotypes, then 
part of the differential cellular and regional vulnerability in 
α-synucleinopathies may be due to different intrinsic proper-
ties of the offending α-syn, expressed at least partially in a 
cell-autonomous way. It remains to be seen if these missense 
mutations give raise to different strains in any way equiva-
lent to their counterpart in sporadic disease, but the fact that 
the E46K mutation inhibits MSA α-syn replication suggests 
that the conformation of the PD-causing mutation E46K is 
different from the strain found in sporadic MSA [185, 191].
A third consequence is that it would be reasonable to 
consider that the level of expression of α-syn could influence 
differential vulnerability, as CNVs causing PD/DLB such 
as the duplications and triplications mentioned, have been 
shown to lead to higher expression of α-syn. These CNVs 
of SNCA vary greatly in size, from ~ 200 kb to > 6 Mb, and 
very often include other genes, although the size or addi-
tional genes do not seem to have a major influence on the 
phenotype [22]. It is thus the higher (but potentially variable 
between cells types) expression of α-syn which appeals as a 
potential mechanism translatable to sporadic disease.
Therefore, and given that SNCA is expressed very widely, 
is SNCA expression higher in vulnerable brain regions/cell 
types in sporadic disease? Review of the Genotype-Tissue 
Expression (GTeX) data suggests the opposite, with the 
median level relatively low in the substantia nigra, although 
there is considerable variation (Fig. 3), and the joint highest 
level being in cerebellar hemispheres, which are generally 
spared in PD [43]. Furthermore, GTEX data do not reveal 
any splicing expression quantitative trait loci (eQTL) in sub-
stantia nigra, which could have led to alternative potentially 
harmful splice variants, or any significant tissue-specific 
eQTL in substantia nigra driving higher expression. The 
picture with regard to MSA is even less clear: the primary 
α-syn pathology lies in oligodendrocytes, although neu-
ronal involvement is increasingly appreciated [48]. There 
have been many doubts about whether α-syn was even 
expressed in oligodendrocytes, although increasing evidence 
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demonstrates that it is, and possibly even at a higher level 
than in DAergic neurons [8, 53]. As these data are from 
homogenates, rather than purely DAergic neurons, review-
ing data from isolated isolated human neurons may be more 
informative. For example, in laser-captured neurons (Suppl. 
Figure 1), the level of expression of α-syn in DAergic neu-
rons has been recently shown to be actually similar to that in 
temporal cortex neurons, although higher than in motor cor-
tex pyramidal neurons [56]. In some brains, the expression 
was highest in substantia nigra DAergic neurons, perhaps 
“tipping the balance” in these cases. All these differences 
could contribute to selective vulnerability.
An important related question to consider is: can substan-
tia nigra DAergic neurons degenerate without α-syn pathol-
ogy? If so, this would suggest that their selective vulnerabil-
ity does not have to depend, at least exclusively, on α-syn. 
This would be the case in parkinsonian disorders such as 
progressive supranuclear palsy in which there is accumula-
tion of tau, rather α-syn, in the substantia nigra. Studies on 
other monogenic forms of PD have also supported this [156]. 
Mutations in PRKN, which cause a recessive young onset 
form of PD, generally do not lead to LBs, or, if they are pre-
sent, they are few and restricted [54]. The most commonly 
mutated gene in late-onset PD, LRRK2, and in particular the 
most frequent mutation G2019S, is generally associated with 
LBs, but this is not the case for all LRRK2 mutations, with 
some cases showing tau pathology or even no specific inclu-
sions [166]. The divergent pathology in cases with LRRK2 
mutations may suggest that LRRK2 lies upstream α-syn and 
tau in the cascade of pathogenic events [5]. While LRRK2 
mutants have been shown to exacerbate the α-syn and tau 
pernicious effects and lrrk2 knockout animals exhibit pro-
tection from α-syn toxicity, it remains to be seen if LRRK2 
toxicity would be abrogated in the absence of α-syn (or tau). 
We do not wish to question the key importance of α-syn 
pathology in sporadic PD, but it clearly appears that in some 
genetic forms a PD phenotype with substantia nigra DAer-
gic loss can result without LB formation. This suggests that 
smaller aggregates may mediate the α-syn pathogenicity, in 
which case the absence of α-syn (or tau) should abrogate 
LRRK2 or PRKN mediated toxicity. If this is the case, these 
theoretical smaller aggregates in LRRK2 and PRKN mutated 
cases without LBs could perhaps be demonstrated with novel 
techniques, such as the recently developed α-syn proximity 
ligation assay (AS-PLA) that we comment on below. Alter-
natively, the selective vulnerability in these cases may be 
conveyed by other factors.
Fig. 3  GTEX expression data. This analysis shows that the median 
expression of SNCA in the substantia nigra (red arrow) is lower than 
some other parts of the brain, e.g., cerebellar hemispheres (green 
arrow). Brain expression is overall high (light yellow plots), although 
high expression is also noted in tibial nerve (dark yellow plot) and 
whole blood (magenta). Vertical axis: transcripts per kilobase million 
(TPM)
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Extensive GWAS have shown several single nucleotide 
polymorphisms (SNPs), including several within the SNCA 
locus, are associated with PD. It is reasonable to expect that 
only a gene expressed in a relevant tissue or cell type could 
exert risk, and many genes expressed in a tissue may exert 
their effect through regulated networks. Significant enrich-
ment for genes highly expressed in relevant tissues and cell 
types was seen in several traits and illnesses [62]. A detailed 
study of mouse forebrain, olfactory, and midbrain neurons 
identified a transcriptional profile of post-mitotic SNc neu-
rons, with two co-expressed gene modules in them associ-
ated with PD pathway KEGG gene sets [84]. PD-associated 
regions from GWAS [39] were significantly enriched for 
genes expressed in DAergic neurons, suggesting that this 
may play a role in their vulnerability. Intriguingly, LRRK2, 
was not expressed in DAergic neurons in this study, leading 
to the suggestion that it may act through microglia. This dif-
ference could help explain the divergent pathology discussed 
above. Other studies, however, have shown LRRK2 expres-
sion in substantia nigra DAergic neurons from mouse and 
human [5, 161]. The way in which SNCA SNPs modulate 
risk is complex, with at least three independent signals, and 
a different pattern in PD and DLB shows that the effect of 
each independent signal is highly phenotype specific [137]. 
The strongest signal in PD is absent in DLB, while the sec-
ondary signal is significant in both. The risk alleles may 
affect transcription sites, leading to different relative abun-
dance of transcripts with varying lengths of untranslated 
regions, and this effect could be tissue or cell-type specific.
The levels of SNCA expression could also be modified by 
epigenetic mechanisms such as DNA methylation. Studies 
on DNA methylation could, therefore, contribute to reveal-
ing tissue- or cell-specific SNCA expression regulation. The 
conflicting studies on this topic have been reviewed [133]. 
One interesting study showed concordant changes in blood 
and frontal cortex, but the substantia nigra was not studied 
[111]. Methylation in the substantia nigra was decreased 
in PD in another study [113], but no cell-type specific data 
in health or disease are available yet to our knowledge. 
There are major technical developments in understanding 
chromatin accessibility at the single cell level, including in 
the human and mouse brain [47, 97]. The substantia nigra 
has not been investigated in these studies, but interestingly 
enrichment for Alzheimer’s disease (AD)-associated SNPs 
was observed in both in microglia, supporting their key role 
in that disease. Dissecting the transcriptome of each cell 
type is expected to advance rapidly with more data from 
the GTEX and the Human Cell Atlas project [148], to help 
address these questions in a more definitive way.
Genome mosaicism
Nuclear genome The nuclear genome of all cells in the 
body was considered to be identical and static, apart from 
cancer and some rare disorders. The topic of brain mosai-
cism, the presence of cells with different genomes due to 
post-zygotic mutations, and a possible role in brain disor-
ders, is now generating a lot of interest [114]. Recent evi-
dence demonstrates multiple recombination events in the 
APP gene occurring in somatic neurons not only in AD 
cases but also in normal neurons, in a process that seems 
to involve age-dependent neuronal “retro-insertion” of RNA 
[100]. Could there be somatic genomic changes in DAer-
gic neurons which make them vulnerable? It is not clear 
if DAergic neurons may be particularly prone to somatic 
mutations, and if so, why this would be, and what sort of 
mutations would arise preferentially. There have already 
been some studies addressing this question. One study 
reported mosaic aneuploidy (gains for both chromosomes 
studied) in PD substantia nigra neuromelanin-positive neu-
rons and proposed aberrant DNA synthesis leading to whole 
genome duplication in these [83]. Another study assessed 
total DNA content in substantia nigra and other neurons; in 
LB diseases, several cell types, including substantia nigra 
pigmented neurons, had higher DNA content than controls, 
but the type of additional DNA was not clear [189]. A recent 
targeted study of the SNCA gene using fluorescence in situ 
hybridization  (FISH) showed low levels of CNVs (gains) 
in DAergic neurons (distinguished by neuromelanin) in 
most PD and MSA cases studied (31/40 and 4/5, respec-
tively) [120]. This phenomenon was seen less frequently in 
controls (10/25), and at a significantly lower overall level, 
and one of these controls did actually have LB pathology 
on further review. These gains were less often seen in non-
pigmented cells. Further work is needed to determine the 
extent to which this is peculiar to the substantia nigra DAer-
gic neurons, and whether it reflects a tendency towards more 
general genomic disturbance. It is also not clear if these may 
have arisen during embryogenesis rather than post-mitoti-
cally, as recent work suggest CNVs are more common in 
younger controls, consistent with an early origin and selec-
tive vulnerability to aging [42].
Mitochondrial genome In contrast to the nuclear genome, 
the mitochondrial genome has long been known to be vari-
able, with heteroplasmy well established. The evidence 
for a role in PD through preferential acquired mutations in 
DAergic neurons has been somewhat contradictory, with 
early reports of deletions being more common in PD. The 
most recent evidence does suggest an excess of deletions, 
but not missense mutations, as well as a failure to increase 
mitochondrial DNA (mtDNA) copy number with age in 
PD, unlike controls [55]. Furthermore, pathway analysis of 
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exome data has shown an enrichment of rare inherited vari-
ation in the pathway controlling mitochondrial DNA repli-
cation and repair, indirectly supporting this as a mechanism 
contributing to disease rather than a result of damage from 
oxidative stress [67]. How do mtDNA mutations in DAer-
gic neurons contribute to PD? Mitochondrial respiratory 
chain dysfunction was reported for complex I in the sub-
stantia nigra 20 years ago [74]. Later, single neuron studies 
showed that complex I and II are the main affected parts 
of the respiratory chain, with complex IV involvement pos-
sibly later or secondary [73]. Although the assumption has 
always been that the complex I deficiency is limited to the 
substantia nigra, and of clear pathogenic relevance, this has 
been challenged by the recent discovery of complex I defi-
ciency in several brain regions in PD, when laser capture 
was used, including spared areas from pathology like the 
cerebellum. Furthermore, the complex I deficiency did not 
correlate with mtDNA damage in areas outside the substan-
tia nigra [64].
Is there something unique about substantia nigra DAer-
gic neurons which leads to DNA damage and secondary 
dysfunction, in the mitochondrial or even nuclear genome? 
α-Syn has been shown in animal and cell models to trigger 
the DNA damage response, possibly leading to single and 
double strand breaks [119]. This is mediated at least partly 
by reactive oxygen species, and specific to DAergic neurons, 
presumably because of the excess ROS generated by DA 
metabolism and the factors discussed above.
Strains and phenotypic diversity
Although, α-synucleinopathies are defined by the presence 
of α-syn inclusions, the exact nature of the inclusions is 
specific to each disease. The variability in these gross struc-
tures may be linked to different upstream conformational 
assemblies that dictate the phenotypic diversity and regional 
vulnerability ultimately resulting in the stereotypical mani-
festations of each disease.
The diversity of α‑syn inclusions
LBs, also known as neuronal α-syn inclusions, are the patho-
logical hallmark of PD and DLB. The structural properties 
of LBs localized in the brainstem or cortices differ. Brain-
stem LBs are more compact, with α-syn fibrils more orderly 
arranged compared to cortical LBs [90, 95]. In MSA, GCIs 
containing α-syn are present in oligodendrocytes. As said, 
the basis for GCIs had been somewhat mysterious as oli-
godendrocytes were thought until recently to express little 
or no α-syn. GCIs have been shown to contain even more 
compacted α-syn than LBs [136], and to be made up of an 
annular α-syn structure [140]. In addition to the biochemical 
and biophysical studies that have shown, these differences in 
structure, distinct properties of brainstem and cortical LBs, 
and GCIs, have been observed by staining with antibodies 
specific for particular α-syn three-dimensional conforma-
tions. For example, one study used the monoclonal anti-
body Syn7015, that seemed to be selective for a particular 
recombinant α-syn aggregate, and showed that GCIs were 
preferentially detected [136], perhaps suggesting inclusions 
were made preferentially of different conformational strains. 
Recently, the AS-PLA, a method that allows visualisation 
of α-syn oligomers in situ with preservation of the cellu-
lar detail, has been developed [150]. Using the AS-PLA 
technique, it was observed that brainstem LBs and GCIs 
were unstained or had punctate staining on their periphery, 
consistent with their compacted fibrillar structure [150]. 
The crown of oligomers around the compact inclusions was 
postulated to reflect either recruitment of oligomers into the 
inclusions or perhaps release of oligomers from them. In 
contrast, cortical LBs displayed strong AS-PLA staining, 
highlighting their distinct structure. As mentioned, it will 
be interesting to see if this and other techniques can demon-
strate α-syn aggregates in LRRK2 and PRKN mutated cases 
without LBs.
Not only do the inclusions seem to have distinctive fea-
tures, but in general terms, their distribution throughout the 
brain would appear to also follow at least partially different 
patterns. In MSA, GCIs are distributed in the olivopontocer-
ebellar system, the nigrostriatal system and the autonomic 
system [162]. PD and DLB are both defined by the presence 
of LBs in the brainstem, limbic and cortical regions (the pre-
dominant pathology in DLB is in limbic and cortical areas, 
while in PD brainstem pathology dominates).
α‑Synuclein strains and the prion‑like hypothesis
The prion‑like hypothesis of α‑syn
Based on neuropathological studies, staging systems for 
the progression of α-syn pathology in PD and DLB were 
proposed [12, 24]. The stereotypical progression of α-syn 
pathology suggested the possibility for a spreading of mis-
folded α-syn along anatomical pathways. This suggestion 
found support in the work of two laboratories which revealed 
that pathological α-syn was detected in healthy DA neurons 
that were transplanted in some PD patients for the treat-
ment of the akinetic–rigid symptoms, suggesting prion-like 
properties for α-syn [70]. These are powerful observations, 
but we must note that the conclusion that these results dem-
onstrate propagation of pathology in humans has been chal-
lenged [60] and alternative mechanisms such as involvement 
of inflammatory responses have been alleged. It has been 
argued that pathology only arose in cases in which small 
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cellular aggregate suspensions or small tissue pieces, which 
elicited extensive microglial activation, were transplanted, 
while a similar number of cases of PD patients with trans-
plants of dissociated neurons, which did not elicit microglial 
response, were perfectly healthy after an equivalent number 
of years [118].
Since then, mounting evidence from cell and animal mod-
els supports the hypothesis that disease can spread through 
the brain by self-propagating α-syn aggregates with templat-
ing ability. In vitro, over-expressed α-syn in SH-SY5Y cells 
was able to transmit to naive SH-SY5Y cells and induce 
inclusion formation [51]. α-Syn pre-formed fibrils (PFFs, 
recombinant α-syn aggregates) were able to seed new aggre-
gation in HEK293 cells overexpressing α-syn or in primary 
neurons expressing endogenous levels of α-syn [109, 178]. 
Injection of PFFs or lysate from the brains of DLB patients 
into mouse brain led to the development α-syn pathology at 
the injection site, which spread to neuroanatomically con-
nected regions [108, 112]. Injection of LB material into the 
striatum of non-human primates resulted in α-syn positive 
staining in the substantia nigra, globus pallidus, precentral 
and superior frontal gyrus and temporal cortex, supporting 
the ability of abnormal α-syn to propagate to distant brain 
regions and to trigger neurodegeneration [147]. In another 
experiment, researchers performed an intracerebral injection 
of α-syn in mouse brains before and after callosotomy to 
dissociate the two brain hemispheres. Results showed that 
the seeding ability of α-syn appeared to be reduced in the 
contralateral hemisphere in the mice that had received cal-
losotomy before α-syn inoculation. On the other hand, in 
the mice receiving callosotomy after α-syn inoculation, the 
pathological protein was found to have been transmitted and 
accumulated to the contralateral hemisphere. Callosotomy 
blocked an important route for α-syn propagation through 
the corpus callosum; however, this was not completely abol-
ished as α-syn might still propagate through limbic routes, 
including hippocampal traffic and the anterior commissure 
[127].
As mentioned, although the evidence supporting 
the hypothesis that α-syn shares properties with pri-
ons is increasing, the applicability of this hypothesis in 
α-synucleinopathies remains controversial. For example, 
there is a significant portion of post-mortem samples that 
are not explained by Braak’s PD staging and it is also evi-
dent that not all cells within a neuroanatomical nucleus are 
equally affected [165]. There is evidence that accumulation 
of α-syn aggregates in the peripheral nervous system, and 
particularly in the peripheral autonomic nervous system, 
precede brain pathology. But why would α-syn spread initi-
ate from the periphery when it is most strongly expressed in 
the brain? It has been argued that peripheral parasympathetic 
neuronal terminals in the gut and olfactory sensory neurons 
in the nose may be exposed to a noxious agent, triggering 
local pathology and subsequent spread. However, no clear 
exposure route to noxious agents is evident for sympathetic 
nerves and ganglia consistently affected early in PD such as 
the cardiac sympathetic nerve [128], while these neurons 
do share cell-autonomous features with other affected areas, 
such as the production of catecholamines. Importantly, no 
cases with α-syn peripheral nervous system pathology with-
out the brain also being affected have been found in 600 
whole-body comprehensive autopsies [105]. More intrigu-
ingly, α-syn aggregates from post-mortem PD stellate sym-
pathetic ganglia failed to promote α-syn pathology in the 
brain of inoculated mice [146]. Other observations that chal-
lenge that the propagation of α-syn pathology emerge from 
its prion-like properties include that the severity of clinical 
progression does not fully correlate with LB pathology pro-
gression and that the strength of connectivity between brain 
areas does not correlate with spreading patterns of α-syn 
[165]. It is possible that some of the gaps in this theory 
reflect the fact that current α-syn immunohistochemical 
methods used so far label late-stage compact aggregates 
such as LBs, Lewy neurites (and GCIs). The novel AS-PLA 
method allowed the authors to identify early aggregation 
stages within cells and a striking previously unrecognised 
neuropil (presumably axonal) oligomeric pathology in ana-
tomical areas not yet affected by LB pathology [150]. It is 
possible that the use of this and similar methods for specific 
protein species may lead to a better definition of the patho-
logical routes of α-syn propagation, perhaps solving some 
of these apparent discrepancies (although surely eliciting 
other questions).
α‑Synuclein strains
In classical prion diseases, a key feature in addition to the 
templating ability of the pathological protein, is the pres-
ence of a variety of strains. The term strain has been used to 
denote distinct pathological aggregates of the prion protein 
that have varying abilities to seed and propagate, and with 
different propensities for seeding aggregation in particu-
lar brain regions. Intense investigation is now focusing on 
whether different α-syn strains exist.
The well-known propensity of α-syn to aggregate has 
been exploited to generate aggregated forms of recombinant 
α-syn protein in vitro. Using this experimental setup, it has 
been well demonstrated that parameters such as salt con-
centration, temperature, cross-linking agents and physical 
force by shaking leads to the formation of α-syn aggregates 
that display distinct structural, biophysical and biochemical 
properties [23, 44, 49, 122]. One study demonstrated that 
varying salt concentrations led to the formation of two struc-
turally distinct aggregates, which they termed fibrils and rib-
bons. Importantly, both structures were able to imprint their 
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structural conformation onto naïve α-syn molecules, a key 
feature of pathological prion proteins [23].
On the other hand, repeated rounds of seeding of α-syn 
PFFs have been shown to lead to the formation of a strain 
that is distinct from de novo PFFs [75]. Interestingly, the 
strain that resulted from multiple rounds of seeding was less 
efficient at seeding new α-syn aggregation but was particu-
larly potent at seeding tau aggregation in vitro and in an 
animal model. Given the hypothesis that PD/DLB pathology 
begins in the brainstem and progresses through the brain 
to the cortex, it is possible that repeated rounds of seed-
ing as the aggregates move through the brain modifies the 
pathological form of α-syn. This may have implications for 
the observed differential structures of brainstem and cor-
tical LBs and for the presence of tau inclusions in cortex 
of patients with PD and DLB, particularly in those with 
dementia.
The studies that utilize in vitro formed aggregates provide 
a proof of principle that α-syn aggregates are capable of self-
propagating and to form different species (and presumably 
strains), but how these forms relate to aggregates present 
in diseased brain is poorly understood. The demonstration 
in multiple studies that brain extracts from patients with 
α-synucleinopathies were sufficient to induce the presence 
and spread of α-syn pathology in animal models provides 
evidence for the presence of self-templating α-syn in dis-
eased brain [112, 143, 183]. They are also starting to show 
differences which could be attributed to different strains. 
In one study, brain extracts from MSA patients, but not 
healthy controls or PD patients, led to neurodegeneration 
in a particular type of α-syn transgenic mice, accompanied 
by α-syn inclusions [143]. Similarly, a recent study proved 
the different spreading capacity of α-syn extracts from MSA 
and DLB patients. Three months after the inoculation of the 
extracts in the striatum of the C57BL/6 mice, the levels of 
MSA-α-syn were enhanced in brain areas including the stria-
tum, frontal cortex, amygdala, and substantia nigra, while 
DLB-α-syn induced low levels of Lewy-neurite-like α-syn 
pathology. The aforementioned findings suggest that unique 
strains of α-syn aggregates are responsible for each disease. 
The exact biochemical differences in the α-syn seeds present 
in MSA or PD brains, and how they relate to their ability 
to preferentially affect certain brain regions or cell types, 
remain unknown. Nevertheless, these properties are strongly 
suspected to underlie part of the differential cellular and 
regional vulnerability in α-synucleinopathies, while at the 
same time different cell types and regions could potentially 
generate or transfer different strains with different efficiency.
Several studies have begun to address this question, for 
example, by injecting two α-syn strains (fibrils or ribbons) 
into rat substantia nigra [23, 135]. Both fibrils and ribbons 
were able to induce α-syn pathology in neurons, but only 
ribbons could seed aggregation in oligodendrocytes. This 
suggests there is a specific conformational feature of the 
ribbon conferring its ability to seed α-syn aggregation in 
oligodendrocytes. Conversely, the cellular environment has 
been shown to influence the strain of α-syn formed. GCI-
derived α-syn has been shown to be approximately 1000-fold 
more potent at seeding new inclusions. Interestingly, α-syn 
PFFs seeded in the presence of rat primary oligodendrocyte 
lysate were able to induce significantly more pathology in 
a cellular model compared with the PFFs generated in rat 
primary neuronal lysate [136]. This suggests the oligoden-
drocyte cellular milieu may promote exceptionally aggres-
sive self-templating forms of α-syn. The specific factors 
mediating such profound differences in the strain formed 
are as yet unknown, but interaction studies with PFFs and 
cell lysates or proteomics to identify enriched proteins in 
α-syn infected oligodendrocytes versus neurons could help 
to shed some light on this. Equally important would be to 
fully resolve what are the endogenous expression levels of 
α-syn in oligodendrocytes, as low levels could impact their 
ability to seed aggregation. Recent evidence from primary 
rat oligodendrocytes suggests that α-syn PFFs triggered the 
aggregation of the endogenous α-syn, which could then not 
be processed by autophagic machinery and led to the ulti-
mate increase of α-syn levels and aggregation within the cell 
[89]. Finally, it is interesting to note that sonication is neces-
sary in order for PFFs to be active in the brain or in culture, 
which inevitably questions the strain itself; are PFFs the only 
strain present in these preparations and, therefore, the main 
drivers of pathology in these experimental paradigms or is 
there also enrichment in other species like oligomers that 
should be considered as well?
As evidence continues to accumulate for the contribution 
of distinct α-syn strains to disease-specific phenotypes, it 
will be important to assess the features of strains derived 
from patient brain. As only small amounts of pathological 
α-syn can be obtained from patient brain, techniques that 
allow the amplification of strains of misfolded proteins such 
as protein misfolding cyclic amplification (PMCA) or real-
time quaking-induced conversion (RT-QuIC) will become 
crucial to allow their properties to be studied in more detail. 
Furthermore, if a therapeutic strategy is intended to target 
α-syn aggregates to prevent their spread, it will be important 
to identify the primary strains, particularly as they may be 
modified as the disease progresses. The convergence of bio-
markers, cohorts of patients at the early stage of the disease 
and efforts to pin down the molecular structures will allow 
these questions to be addressed. We believe that understand-
ing the properties of different α-syn strains is key. The fact 
that different strains of α-syn are associated with particular 
α-synucleinopathies and may even vary throughout disease 
progression could also reflect the ability for different struc-
tures of α-syn to interact with specific biological partners 
[59, 173]. Therefore, understanding these interactions will 
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also potentially allow us to develop novel biomarkers for 
α-synucleinopathies throughout their progression, which is 
essential for clinical trials (cohort selection and effectiveness 
measures), and the development of new therapeutics based 
on sound scientific rationale.
Exogenous and environmental factors 
modulating selective regional vulnerability
We have discussed so far how the interplay of intrinsic 
cellular and anatomical factors of the affected popu-
lations, including their genetic background, together 
with different α-syn strains with capacity for self-
templating are thought to explain the pathogenesis of 
α-synucleinopathies and their phenotypic diversity. 
However, exogenous and environmental factors such as 
neurotoxins, heavy metals, brain trauma and sleep dis-
orders have also been implicated in neurodegenerative 
α-synucleinopathies [41]. We will discuss some of these 
factors and how they could contribute to the selective cel-
lular and regional vulnerability in α-synucleinopathies.
Neurotoxins
Several studies support that treatment with neurotoxins 
inhibiting the mitochondrial complex I and causing oxida-
tive stress like MPTP, paraquat, and rotenone enhance the 
risk of developing α-syn pathology.
MPTP
The injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP) induces a rapid PD-like syndrome. MPTP 
can be accidentally synthesized when attempting to pro-
duce the opioid analgesic drug desmethylprodine, also 
called 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP). 
The neurotoxicity derived after the injection of MPTP was 
discovered in a patient in 1976 and a further four patients 
in 1983 that had illegally used MPPP contaminated with 
MPTP. Although MPTP itself is not toxic, it readily crosses 
the blood–brain barrier and is subsequently metabolised to 
the toxic 1-methyl-4-phenylpyridinium  (MPP+) which is 
uptaken by DA transporters into the neurons. By accumu-
lating into mitochondria,  MPP+ inhibits complex I leading 
to energy failure and oxidative stress [145]. As mentioned, 
the highly elongated and branched axons of the DAergic 
neurons in substantia nigra require high levels of energy that 
can be barely provided by the mitochondria. Therefore, the 
morphology and the increased energy demands of nigrostri-
atal DAergic neurons make them more vulnerable to MPTP 
compared to the DAergic neurons in the VTA [155]. It is 
clear from the early reported cases of parkinsonism due to 
MPTP that transient exposure to MPTP results in reduc-
tion in nigrostriatal DAergic function [10]. Researchers 
have also revealed upregulation of α-syn in DAergic neu-
rons after administration of MPTP [176]. Although MPTP 
triggers α-syn accumulation, the extensive deposition of the 
LBs and neurites observed in PD cases, is not observed in 
MPTP models, even after a decade administration of MPTP 
[78]. Instead of LBs, α-syn amorphous bundles are observed 
[115]. This finding indicates that oxidative stress, inflamma-
tion, and cytotoxicity are not the only mechanisms contribut-
ing to LBs formation. Other mechanisms must also contrib-
ute to the protein aggregation in LBs [78]. Brain analysis of 
MPTP-lesioned non-human primates displayed a significant 
escalation in α-syn mRNA levels after 1 week or 1 month of 
MPTP treatment, with the protein being accumulated in the 
cell bodies of DAergic neurons [144]. Other studies support 
that overexpression of α-syn in mice enhances the vulnera-
bility of substantia nigra DAergic neurons, while deletion of 
the protein in α-syn null mice reduces MPTP toxicity [50]. 
These studies indicate the participation of α-syn to pathways 
essential for DAergic neuron viability and alterations in the 
expression or mutations of SNCA can modulate the vulner-
ability of these neurons to a specific neurotoxin. Indeed, mis-
folded α-syn can induce activation of brain immune cells, 
enhanced inflammation and production of ROS making the 
DAergic neurons more susceptible to MPTP [99]. While 
accumulation of α-syn in the glial cells has been described 
in α-synucleinopathies [169, 180], α-syn accumulation was 
not detected neither in microglia nor astrocytes in a study 
with a primate MPTP model [115].
Paraquat
Paraquat (N,N′-dimethyl-4,4′-bipyridinium dichloride) is a 
toxic herbicide which increases cytoplasmic oxidative stress 
and inflammation in the midbrain leading to the selective 
degeneration of substantia nigra DAergic neurons [116]. 
Paraquat enhances the production of DA, resulting in the 
formation of toxic quinoproteins that affect the normal 
function of numerous proteins, including α-syn, and lead to 
cell death, explaining the specificity of paraquat for DAer-
gic neurons [17]. Treatment of A53T mutant human α-syn 
transgenic mice (TgM83) with both paraquat and maneb, an 
inhibitor of complex III, but not with each substance alone, 
enhanced also the formation of α-syn inclusions in brain-
stem, striatum, and thalamus [125]. The temporal expression 
of the pathological protein is also affected by this herbicide 
[123]. According to Braak’s theory, α-syn distribution initi-
ates in body areas other than the brain, like enteric nervous 
system (ENS) and olfactory bulb [13]. In a recent study, 
researchers proved that oral administration of paraquat in 
TgM83 mice led to an earlier expression of the pathologi-
cal α-syn in the ENS, while this precocious expression was 
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not observed in the brain of the mice [123]. At this point, 
it is essential to mention that the exposure to paraquat of 
non-transgenic or transgenic mice expressing the wild-type 
human α-syn did not induce α-syn pathology, underlying 
that in this case, the interaction between the genetic and 
environmental factors is essential for the progression of the 
α-synucleinopathy [123, 125].
Rotenone
Another identified pesticide that is associated with α-syn 
pathology is rotenone, also known for inhibiting mitochon-
drial complex I and producing ROS, in all cell types [104]. 
However, DAergic neurons, appeared to be highly affected 
compared to other types of neurons due to the rotenone-
induced oxidation of DA [149]. The increased production 
of ROS as well as the anatomical features of the substantia 
nigra DAergic neurons explain the selective vulnerability 
of this cell type to rotenone [21]. In a process with parallel-
isms with MPTP toxicity, it has been shown that rotenone 
exposure upregulates α-syn and triggers α-syn oligomeriza-
tion [190]. However, and in contrast with MTPT, a recent 
study supported that unilateral intracranial infusion of rote-
none in the medial forebrain bundle and substantia nigra in 
mouse brain increase dramatically the bilateral aggregation 
of α-syn in substantia nigra, but not in the striatum, causing 
substantia nigra degeneration and motor disabilities [35]. 
Another study showed that rotenone induced the formation 
of eosinophilic inclusions similar to the pale body precursors 
of LBs [16], while western blotting analysis of rotenone-
induced α-syn revealed α-syn forms with high molecular 
weight corresponding to dimers, trimers, and post-transla-
tional modified proteins [71]. Finally, the spreading capacity 
of these rotenone-induced α-syn forms between neurons was 
investigated by another group, where researchers using pri-
mary neuronal cell cultures proved that rotenone can initiate 
the progression of α-syn pathology through transneuronal 
and retrograde axonal transport by increasing the number of 
exosomes participating to α-syn release [130]. Both MPTP 
and rotenone share a mechanism of being mitochondrial poi-
sons and that both increase expression of α-syn. However, 
there seem to be crucial differences, with rotenone, but not 
MPTP, being able to form inclusions more similar to PD and 
to induce the spread of pathology. It is possible that the dif-
ferences relate to intrinsic chemical/toxicological properties 
of these substances. However, given that MPTP acts largely 
exclusively in DAergic cells, it is possible that inclusion 
formation and spread require not only DAergic cell-autono-
mous factors but assistance from other non-cell-autonomous 
factors generated from the other neuronal and/or glial cell 
types. A differential concourse of these factors may also lead 
to differential cellular and regional vulnerability.
Heavy metals
Another important environmental factor that is highly asso-
ciated with α-syn pathology is the exposure to heavy metals 
like copper, manganese, and iron.
Iron
Iron is a well-described metal linked to α-synucleinopathies, 
with numerous studies suggesting an iron concentration 
increased in brain areas like the substantia nigra, putamen 
and globus pallidus in patients with PD, MSA, and DLB 
[88]. Iron has a synergistic interaction with α-syn. On the 
one hand, intracellular α-syn facilitate the accumulation of 
intraneuronal iron, while on the other hand, iron promote 
the oligomerisation of α-syn. More specifically, the Fe(II) 
ion commits N-terminally acetylated α-syn, believed to be 
a physiologically relevant form in humans more resistant to 
oligomerisation [31], to a PD-relevant oligomeric assem-
bly with a right-twisted antiparallel β-sheet component [2]. 
One study showed that iron induces reduction of the levels 
of autophagic related proteins in primary neurons and SH-
SY5Y cells impairing the autophagy system and leading to 
the accumulation of α-syn [181]. Focusing also in the lyso-
somal–autophagic system, a study proved that iron-induced 
activation of Akt/mTOR axis in mouse midbrain substantia 
nigra cells expressing α-syn may be involved in prevent-
ing transcription factor EB (TFEB) nuclear translocation, 
inhibiting in this way the autophagosome–lysosome fusion 
and triggering α-syn aggregation and transmission to the 
neighbour cells [186]. While a correlation between iron-
overloaded disorders and parkinsonism has been reported 
[124], other study showed that patients with iron-overload 
disorder do not have an increased susceptibility to parkin-
sonism [1]. In contrast, neurodegeneration with brain iron 
accumulation, a group of inherited neurologic disorders in 
which iron accumulates in the basal ganglia, show wide-
spread α-syn LB (and tau) accumulation, particularly those 
harbouring PLA2G6 mutations [129].
Copper
Copper is an element that plays a pivotal role in a number 
of mechanisms including the synthesis of neurotransmitters, 
oxygen consumption and cell signalling [41]. Both oxidative 
states of copper can bind α-syn [172] and copper exposure 
appears to accelerate the progression of α-syn pathology 
[66] through at least two possible mechanisms. In the first 
one, the interaction of copper with α-syn affects its helical 
conformation leading to its oligomerisation, while in the 
second one, copper induces the oxidation of α-syn caus-
ing its accumulation [36]. However, a protective role for 
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copper has also been proposed. It has been suggested that 
the presence of copper may induce the formation of less-
damaging structurally different α-syn strains showing greater 
ability to form less cytotoxic intracellular inclusions. These 
experiments would strengthen the opinion that LBs may be 
protective bystanders and that α-syn oligomers are the toxic 
species [177]. Interestingly, the H50Q variant affects cop-
per binding [142], although as discussed, its pathogenicity 
has been questioned. Copper-related disorders like Wilson’s 
disease can present as a parkinsonism with dystonic tremor 
but, in contrast to disorders with iron accumulation, no LBs 
or α-syn accumulation is seen, suggesting that copper accu-
mulation in these cases may not act through an α-syn-related 
mechanism.
Manganese
Another metal related to α-synucleinopathies is manganese. 
Manganese homeostasis is vital for energy metabolism, 
enzymes function, and immune reaction [40]. Chronic expo-
sure to manganese has multiple neurological effects includ-
ing the increased susceptibility of α-syn to form inclusions 
[79]. Manganese accumulates mainly in basal ganglia and 
mostly in globus pallidus, increasing in this way the vulner-
ability of the cells in this region [96] and manganese expo-
sure resulted in α-syn accumulation triggered by ER stress 
in mouse neuroblastoma cells expressing human α-syn [9].
Traumatic brain injury
Neuronal dysfunction and cell death induced by acute con-
ditions like traumatic brain injury (TBI) seem mediated 
by enhanced inflammation, mitochondrial dysfunction, 
oxidative and ER stress, pathological mechanisms that 
have a crucial role in the development and progression of 
α-synucleinopathies [4]. Post-mortem analysis of human 
brain following TBI has revealed positive staining for α-syn, 
highly associated with axonal pathology [171]. In a recent 
study to investigate the link between TBI and neurodegen-
erative disorders, 5–6-week-old mice were exposed to multi-
ple condition head impacts and the levels of several proteins 
were examined. The results showed that after repetitive TBI, 
there was an increase in brain amyloid β, tau, and α-syn in a 
dose-dependent manner [102]. α-Syn accumulation has also 
been detected in glial cells [3], predominantly in microglia 
compared to astrocytes [85]. Microglia probably serves the 
double role of uptaking α-syn for clearance and to initiate 
an immune response by acting as an antigen presenting cell 
[61]. Consistently, a previous research proved that chronic 
TBI rats presented overexpression of α-syn in the ipsilateral 
rather in the contralateral substantia nigra 60 day post-TBI. 
This increased accumulation of α-syn was correlated with 
enhanced activation of microglial cells around the area of the 
injury [3]. Chronic activation of microglia and other brain 
immune cells results in chronic neuroinflammation through 
the production of pro- and anti-inflammatory mediators and 
reactive species leading to intraneuronal oligomerisation of 
α-syn [121]. α-Syn fibrils, in turn, enhance the recruitment 
of brain immune cells to the injured area of the brain creat-
ing a vicious cycle and promoting neurodegeneration [58, 
151]. Therefore, the injured brain regions appeared to be 
more vulnerable in developing α-syn pathology.
Circadian rhythm alterations
An association between circadian rhythm alterations and 
some neurodegenerative diseases has been reported. This 
association could be the consequence of the spread of dis-
ease to involve the neuroanatomical substrates of circadian 
rhythm regulation. Alternatively, or in addition to this, it is 
also possible that alterations in the circadian rhythm could 
modify brain function and make it more susceptible to neu-
rodegeneration, for example by altering protein homoeosta-
sis and immune function. If that was the case, restoration 
of sleep patterns could have a role as a preventive or thera-
peutic intervention. Altered circadian rhythms have been 
found to be associated with a higher risk for mild cognitive 
impairment (which often preludes the development of AD) 
or even clinical dementia [168]. Altered circadian rhythms 
are also found in α-synucleinopathies. RDB is a sleep altera-
tion taking place during the REM phase of sleep, the phase 
in which the most vivid dreams occur. This phase is nor-
mally characterised by muscular atonia. In RDB there is a 
loss of muscle atonia resulting in patients acting out their 
(frequently unpleasant) dreams with complex behaviours. 
A large proportion of patients with RBD evolve into a clini-
cal α-synucleinopathy after 5 to 14–16 years [86]. Interest-
ingly, from this common initial manifestation the patient 
can develop either PD, MSA or DLB. The anatomical sub-
strate of RBD is not completely clear. Candidates include 
dorsal midbrain and pons [19], particularly the peri-locus 
coeruleus and sublaterodorsal nucleus (SLD) [20]. These are 
either sites of accumulation of α-syn in brain regions at early 
Braak’s PD stages or sites connected to them. For example, 
glutamatergic neurons of the SLD possess descending pro-
jections into the medulla, one of the earliest affected brain 
regions in LB disorders [19]. Importantly, autopsy studies 
have confirmed that RBD cases display α-syn deposition 
in the olfactory bulb, brainstem, and amygdala (all areas 
frequently affected in LB disorders) before converting into 
clinical PD or MSA [86]. The function of neurons at these 
sites is modified by circadian rhythm mechanisms (for exam-
ple daily rhythms in circadian clock gene expression), and 
therefore, it is possible that these mechanisms may impinge 
upon physiological and also pathological elements that 
could influence pro-neurodegenerative aggregation [80]. As 
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mentioned, disentangling cause and effect is even more chal-
lenging in these cases. However, and given that this could 
be potential therapeutic target, we think more studies are 
warranted to clarify if sleep disturbances could be causing 
or contributing to neurodegeneration. For example, if cer-
tain types of sleep disturbance or even near-normal routines/
patterns of sleep (or frequent sleep deprivations) during life 
could influence the process of disease generation and spread 
through conveying differential cellular and regional vulner-
ability, or if, alternatively, a healthy sleep pattern may have 
a neuroprotective role.
Microbiota, infections and dietary factors
The possibility that microorganisms could be causing or 
triggering PD arose after the 1920–1930s influenza epi-
demic, which was associated with encephalitis lethargica, 
a disease that resulted in a PD-like akinetic–rigid syndrome 
[117]. However, no definite proof for this or any other 
virus has been found in human brain so far as causatives of 
α-synucleinopathies. After decades in which new viruses 
were being postulated but never proven, the hypothesis that 
an environmental agent such as a virus, bacteria or misfolded 
protein was triggering the disease re-emerged with the Braak 
hypothesis, who postulated that such an agent could be 
entering through the nose or the gut [81]. Vertebrate food 
products have been suggested, but not yet proven, as a poten-
tial trigger of α-syn pathology through the ingestion of a 
misfolded α-syn inoculum from animal source [92]. Recent 
evidence suggests that gut microbes promote the motor dys-
function and brain pathology mediated by α-syn [153]. In 
this case, modulation of neuroinflammation, rather than a 
direct mechanism, has been suggested. While the importance 
of these hypotheses for the development and progression of 
the human disease remains to be fully determined, the dif-
ferent route of entry for these agents (e.g., nose or gut) and 
the mechanisms proposed (e.g., direct entry versus gut–brain 
neuroinflammatory axis) add more putative mechanisms to 
explain the differential vulnerability and resulting pheno-
typic variability of these disorders.
Conclusion
It is clear that α-syn has the central role in the group of dis-
orders referred to as α-synucleinopathies. We are just start-
ing to understand how the combination of the niche physiol-
ogy of highly specialised neurons and glia, and the extensive 
scope of α-syn biology gives rise to an intersecting web of 
factors that determine α-synucleinopathies aetiology and 
progression. We believe that there are several key develop-
ments that could unlock our understanding of the differential 
cellular and regional vulnerability in α-synucleinopathies 
and ultimately open the route to disease-changing treat-
ments. These include, for example, the ability to specifically 
visualise and measure robustly the different endogenous 
types of α-syn supramolecular arrangements (conforma-
tional variants, species, strains) in biological samples from 
early time points in the disease, coupled with the develop-
ment of non-invasive, e.g., imaging-based tests, capable of 
correlating with these biological measurements. While these 
tools could help resolve temporal and spatial pathophysio-
logical factors, we also believe that an increase in innovative 
human post-mortem studies is also essential in ultimately 
proving novel hypotheses. As for now, we can only specu-
late that the disruption of the cellular metabolic state, α-syn 
structural equilibrium, and anatomical connectivity appears 
to initiate cascades of pathological processes triggered by 
genetic, environmental or stochastic events that result in the 
“death by a thousand cuts” profile of α-synucleinopathies.
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